Modern Pathology, Artificial Intelligence and Personalized Therapy in Gastrointestinal Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 September 2024 | Viewed by 142
Special Issue Editor
Special Issue Information
Dear Colleagues,
Gastrointestinal (GI) cancers occur with high prevalence and mortality in the United States and worldwide. Early diagnosis and optimized therapy remain major challenges in the treatment of GI cancer. Personalized cancer therapy is a new approach that involves tailoring prevention and treatment recommendations to the individual patient based on their genetic/genomic characteristics and tumor-related biomarkers. Its evolution has instigated a new era in the fight against cancer.
Advancements in technology and molecular diagnostics have increased our understanding and interpretation of the genomic and proteomic properties of cancers, and revealed many specific biomarkers that are now being incorporated into diagnostic and treatment decision-making algorithms. Molecular pathology is rapidly becoming a cornerstone of personalized therapy for cancers, including GI cancers.
Digital pathology initiated the shift from traditional histopathology using microscopy to virtual images on the computer, and has promoted the use of artificial intelligence (AI) and machine learning (ML) by pathologists in clinical practice. AI in pathology comprises computational search algorithms, machine learning, and deep learning models. AI has been used to identify novel diagnostic and prognostic biomarker signatures on tissue images of various types of cancer, and has also been used to create more quantitative, detailed, objective, and reproducible assessments of these tissue biomarkers.
This Special Issue of Cancers aims to introduce the latest original studies and reviews on molecular biomarkers, digital pathology, and personalized therapy in GI cancers.
Dr. Wenqing Cao
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- molecular pathology
- biomarkers
- digital pathology
- targeted therapy
- gastric cancer
- colon
- liver
- pancreas
